Skip to content
NBDC Human Database

No datasets in the cart.

Go to the cart

Due to system maintenance, the application system, application review by the Data Access Committee will be unavailable during the following period.
Schedule: October 5th (Mon), 2026, 9:00 - October 7th (Wed), 2026, 15:00 (JST)
We apologize for any inconvenience this may cause and appreciate your understanding.

We are currently receiving a large number of applications for data submission, and the review process is taking longer than usual.We sincerely apologize for the delay and kindly ask for your understanding. When submitting an application, we would greatly appreciate it if you could allow sufficient time for the processing.

Following a change to our organizational structure effective April 1, 2026, this division has been renamed from the "Database Center for Life Science, Joint Support-Center for Data Science Research" to the "Database Division for Life Science (DBCLS), BioData Science Initiative (BSI), National Institute of Genetics (NIG)". Where the former name still appears in the guidelines, please read it as the new name.

Research ID

hum0409-v1Release info

Latest

Research title

Analysis of genes that confer exceptional response in anticancer therapy

Research overview

Aims
To identify genetic abnormalities that cause Exceptional Response in cancer drug therapy with VEGFR inhibitors, multi-kinase inhibitors, cytotoxic anticancer drugs, and others. Based on this information, we aim for early participation in clinical trials, acquisition of POC through off-label use, and development into investigator-initiated and corporate clinical trials.
Methods
Whole exome sequencing, Exome RNA sequencing, cfDNA target sequencing
Participants/materials
FFPE tumor tissue DNA (13 samples) and RNA (12 samples), control normal blood cell DNA (11 samples), cell-free DNA (cfDNA) in blood (26 samples) from 11 cases of intimal sarcoma with MDM2 amplification
URL

Datasets

CartDataset IDType of dataAnalysis methodAccess criteriaDate published
JGAD000748NGS (Exome)
NGS (RNA-seq)
NGS (Target Capture)
  • WES
  • RNA-seq
  • Targeted DNA sequencing
Controlled-access (Type I)2023-06-27

Data provider

Principal investigator
Takafumi Koyama
Affiliation
Department of Experimental Therapeutics, National Cancer Center Hospital

Research projects

NameURL
NCCH1806
N/A

Grants

NameTitleProject number
Project Promoting Clinical Trials for Development of New Drugs, Japan Agency for Medical Research and Development (AMED)
Comprehensive research for clinical development and infrastructure development of super-rare cancers through the Clinical Innovation Network project of the oncology
  • JP16lk0201044
The National Cancer Center Research and Development Fund
Development of the precision liquid biopsy and evaluation of its feasibility and clinical utility
  • 2022-A-02

Related publications

TitleDOIDataset ID
Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification
https://doi.org/10.1158/2159-8290.CD-23-0419 (opens in a new tab)

Controlled access users

No use of the controlled access data has been recorded.